Spironolactone ameliorates podocytic adhesive capacity via restoring integrin α3 expression in streptozotocin-induced diabetic rats

JRAAS - Journal of the Renin-Angiotensin-Aldosterone System

Volumn 11, Issue 3, 2010, Pages 149-157

  Lin, Shan ^a   Li, Dong ^a   Jia, Junya ^a   Zheng, Zhenfeng ^a   Jia, Zhonghui ^a   Shang, Wenya ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

Author keywords

diabetic nephropathy; integrin; podocyte; spironolactone

Indexed keywords

ALBUMIN; ALPHA3 INTEGRIN; SPIRONOLACTONE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL ADHESION; CONTROLLED STUDY; DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; HISTOPATHOLOGY; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PODOCYTE; PROTEIN EXPRESSION; RAT; STREPTOZOCIN DIABETES; UPREGULATION; URINARY EXCRETION; URINE LEVEL; URINE SEDIMENT; WESTERN BLOTTING;

ALBUMINURIA; ANIMALS; CELL ADHESION; DIABETES MELLITUS, EXPERIMENTAL; INTEGRIN ALPHA3BETA1; MALE; PODOCYTES; RATS; RATS, WISTAR; SPIRONOLACTONE; UP-REGULATION; URINE;

EID: 77956297974     PISSN: 14703203     EISSN: None     Source Type: Journal    
DOI: 10.1177/1470320310369603     Document Type: Article

References (37)

1. Mauer M., Zinman B., Gardiner R., et al. ACE-I and ARBs in early diabetic nephropathy. J Renin Angiotensin Aldosterone Syst 2002 ; 3: 262-269.
2. Susztak K., Raff AC, Schiffer M., and Bttinger EP Glucose-induced reactive oxygen species cause apoptosis of podocytes and podocyte depletion at the onset of diabetic nephropathy. Diabetes 2006 ; 55: 225-233.
3. Lehman DM, Leach RJ, Johnson-Pais T., et al. Evaluation of tight junction protein 1 encoding zona occludens 1 as a candidate gene for albuminuria in a Mexican American population. Exp Clin Endocrinol Diabetes 2006 ; 114: 432-437.
4. Toyoda M., Najafian B., Kim Y., Caramori ML, and Mauer M. Podocyte detachment and reduced glomerular capillary endothelial fenestration in human type 1 diabetic nephropathy. Diabetes 2007 ; 56: 2155-2160.
5. Whiteside C., Prutis K., Cameron R., and Thompson J. Glomerular epithelial detachment, not reduced charge density, correlates with proteinuria in Adriamycin and puromycin nephrosis. Lab Invest 1989 ; 61: 650-660.
6. Yu D., Petermann A., Kunter U., Rong S., Shankland SJ, and Floege J. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria. J Am Soc Nephrol 2005 ; 16: 1733-1741.
7. Hynes R. Integrins: Versatility, modulation and signaling in cell adhesion. Cell 1992 ; 69: 11-25.
8. Kitsiou PV, Tzinia AK, Stetler-Stevenson WG, et al. Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells. Am J Physiol Renal Physiol 2003 ; 284: F671 - F679.
9. Cha DR, Kang YS, Han SY, et al. Role of aldosterone in diabetic nephropathy. Nephrology (Carlton) 2005 ; 10 (Suppl): S37 - S39.
10. Good DW Nongenomic actions of aldosterone on the renal tubule. Hypertension 2007 ; 49: 728-739.
11. Shibata S., Nagase M., Yoshida S., Kawachi H., and Fujita T. Podocyte as the target for aldosterone: roles of oxidative stress and Sgk1. Hypertension 2007 ; 49: 355-364.
12. Rossing K., Schjoedt KJ, Smidt UM, Boomsma F., and Parving HH Beneficial effects of adding spironolactone to recommended antihypertensive treatment in diabetic nephropathy: a randomized, double-masked, cross-over study. Diabetes Care 2005 ; 28: 2106-2112.
13. Nakamura T., Ushiyama C., Shimada N., et al. Effect of the antiplatelet drug dilazep dihydrochloride on urinary podocytes in patients in the early stage of diabetic nephropathy. Diabetes Care 2000 ; 23: 1168-1171.
14. Inada A., Nagai K., Arai H., et al. Establishment of a diabetic mouse model with progressive diabetic nephropathy. Am J Pathol 2005 ; 167: 327-336.
15. White KE, Bilous RW Estimation of podocyte number: a comparison of methods. Kidney Int 2004 ; 66: 663-667.
16. Sato A., Hayashi K., Naruse M., and Saruta T. Effectiveness of aldosterone blockade in patients with diabetic nephropathy. Hypertension 2003 ; 41: 64-68.
17. Siragy HM, Xue C. Local renal aldosterone production induces inflammation and matrix formation in kidneys of diabetic rats. Exp Physiol 2008 ; 93: 817-824.
18. Fujisawa G., Okada K., Muto S., et al. Spironolactone prevents early renal injury in streptozotocin-induced diabetic rats. Kidney Int 2004 ; 66: 1493-1502.
19. Sato A., Hayashi K., and Saruta T. Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005 ; 18: 44-49.
20. Schjoedt KJ, Rossing K., and Juhl TR Beneficial impact of spironolactone on nephrotic range albuminuria in diabetic nephropathy. Kidney Int 2006 ; 70: 536-542.
21. Guo C., Martinez-Vasquez D., and Mendez GP Mineralocorticoid receptor antagonist reduces renal injury in rodent models of types 1 and 2 diabetes mellitus. Endocrinology 2006 ; 147: 5363-5373.
22. Gross ML, El-Shakmak A., Szabo A., et al. ACE-inhibitors but not endothelin receptor blockers prevent podocyte loss in early diabetic nephropathy. Diabetologia 2003 ; 46: 856-868.
23. Pagtalunan ME, Miller PL, Jumping-Eagle S., et al. Podocyte loss and progressive glomerular injury in type II diabetes. J Clin Invest 1997 ; 99: 342-348.
24. Meyer TW, Bennett PH, and Nelson RG Podocyte number predicts long-term urinary albumin excretion in Pima Indians with type II diabetes and microalbuminuria. Diabetologia 1999 ; 42: 1341-1344.
25. Vogelmann SU, Nelson WJ, Myers BD, and Lemley KV Urinary excretion of viable podocytes in health and renal disease. Am J Physiol Renal Physiol 2003 ; 285: F40 - F48.
26. Petermann AT, Pippin J., Krofft R., et al. Viable podocytes detach in experimental diabetic nephropathy: potential mechanism underlying glomerulosclerosis. Nephron Exp Nephrol 2004 ; 98: e114 - e123.
27. Aberdam D., Galliano MF, Vailly J., et al. Herlitz's junctional epidermolysis bullosa is genetically linked to mutations in the nicein/kalinin (laminin 5) LAMC2 gene. Nat Genet 1994 ; 6: 299-304.
28. Cosio FG Cell-matrix adhesion receptors: relevance in glomerular pathology. Am J Kidney Dis 1992 ; 20: 294-305.
29. Rahilly M., Fleming S. Differential expression of integrin alpha chains by renal epithelial cells. J Pathol 1992 ; 167: 327-334.
30. Chen HC, Chen CA, Guh JY, Chang JM, Shin SJ, and Lai YH Altering expression of alpha3beta1 integrin on podocytes of human and rats with diabetes. Life Sci 2000 ; 67: 2345-2353.
31. Zatz R., Meyer TW, Rennke HG, and Brenner BM Predominance of hemodynamic rather than metabolic factors in the pathogenesis of diabetic glomerulopathy. Proc Natl Acad Sci U S A 1985 ; 82: 5963-5967.
32. Forbes JM, Fukami K., and Cooper ME Diabetic nephropathy: where hemodynamics meets metabolism. Exp Clin Endocrinol Diabetes 2007 ; 115: 69-84.
33. Seyer-Hansen K. Renal hypertrophy in experimental diabetes: some functional aspects. J Diabetes Complications 1987 ; 1: 7-10.
34. Ingram AJ, Scholey JW Stress-responsive signal transduction mechanisms in glomerular cells. Curr Opin Nephrol Hypertens 2000 ; 9: 49-55.
35. Dessapt CBM, Hayward A., Viberti G., and Gnudi L. TGFβ1 and mechanical stretch reduce murine podocyte adhesion to extracellular matrix substrate and modulate β1 integrin expression/maturation in vitro. Diabetologia 2005 ; 48 (Suppl 1). A28 (abstract).
36. Kojima K., Matsui K., and Nagase M. Protection of alpha(3) integrin-mediated podocyte shape by superoxide dismutase in the puromycin aminonucleoside nephrosis rat. Am J Kidney Dis 2000 ; 35: 1175-1185.
37. Cortinovis M., Perico N., Cattaneo D., Remuzzi G., and Cortinovis M. Aldosterone and progression of kidney disease. Ther Adv Cardiovasc Dis 2009 ; 3: 133-143.